Telix Stock And Other Fast Growing Insider Owned Shares Worth A Closer Look
With central banks watching inflation, energy prices swinging and tariffs back in focus, many investors are looking for companies that are not just growing, but whose leaders have real skin in the game. The Fast Growing Stocks With High Insider Ownership screener targets exactly that kind of stock, combining strong growth potential with management teams that are financially aligned with shareholders. In a world where services sectors are holding up, manufacturing signals are mixed and bond yields are higher, this theme can help you focus on businesses where insiders appear confident. Below, you will see 3 of the stocks from this screener.
Predictive Discovery (ASX:PDI)
Overview: Predictive Discovery is an Australia based gold company focused on exploring and developing the Bankan Gold project in north east Guinea, a 356 square kilometre land package in West Africa that it aims to turn into an economic gold producing hub.
Market Cap: A$3.33b
Predictive Discovery is attracting attention because it blends a sizeable A$3.33b market cap with a growth heavy story, as analysts see earnings and revenue rising sharply from today’s small base while the Bankan project and existing West African operations scale up. At the same time, the stock is flagged as trading well below analyst estimated fair value, even though it carries a rich P/B multiple and is still loss making with a recent net loss of A$8.99 million in Q3 and A$21.87 million over nine months. Add in a short cash runway, reliance on external funding and recent insider selling, and you have a high potential but high risk gold developer that warrants closer inspection.
Accelerating interest in Predictive Discovery hinges on whether the growth heavy story really justifies the current risks, so it is worth reading the 2 key rewards and 4 important warning signs (2 are major!) to see what could tilt the balance next
Mesoblast (ASX:MSB)
Overview: Mesoblast is a Melbourne based biotech company developing regenerative medicines that use mesenchymal lineage cells to treat severe inflammatory and cardiovascular conditions, including pediatric graft versus host disease, chronic low back pain and chronic heart failure, through products such as Ryoncil and rexlemestrocel L and a network of global partners.
Operations: Mesoblast generates around US$65.4 million in revenue from developing its cell technology platform for commercialization.
Market Cap: A$3.02b
Mesoblast may stand out for some investors because it operates at the intersection of commercial cell therapy and a broad late stage pipeline. Ryoncil is already generating product revenue, and rexlemestrocel L is being advanced in large markets such as chronic low back pain and heart failure under RMAT and Orphan Drug designations. The company remains loss making and relies on external funding, including a recent US$50 million debt facility. The stock also trades below some fair value estimates, while its P/S ratio appears relatively high, which highlights a tension between growth expectations and execution risk that some investors may wish to consider further.
Mesoblast sits at the crossroads of real product revenue and a late stage cell therapy pipeline, and the market may not be pricing that mix clearly. Get the fuller picture with the analysis report for Mesoblast
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors both detect and treat cancers, using targeted imaging agents and therapies across prostate, kidney, brain and other solid tumors in markets including the United States, Europe and Asia.
Operations: Telix generates most of its revenue from Precision Medicine at about US$621.9 million, with Manufacturing Solutions contributing roughly US$245.1 million and Therapeutics about US$9.3 million, partly offset by US$72.5 million in inter segment eliminations.
Market Cap: A$5.15b
Telix Pharmaceuticals is turning its radiopharmaceutical platform into a sizeable commercial business, with Precision Medicine products Illuccix and Gozellix already used across more than 23 countries and FY2026 revenue guidance in the range of US$950 to US$970 million supported by recent quarterly revenue of US$247 million. The stock currently reflects forecasts for double digit revenue growth and strong expected earnings growth, yet it still carries clinical, regulatory and funding risks, including an SEC subpoena, higher R&D and manufacturing spend, and reliance on successful late stage trials such as ProstACT Global and IPAX BrIGHT. For investors who can tolerate those risks, Telix combines a growing commercial footprint, an expanding manufacturing base and a broad cancer therapy pipeline that the market may not be fully reflecting today.
Telix Pharmaceuticals is building a sizeable radiopharmaceutical business, but many investors may still be focused on headline revenue and trial news while overlooking what comes next in the analyst forecasts for Telix Pharmaceuticals.
The three stocks in this article are just a starting point, and the full Fast Growing Stocks With High Insider Ownership screener on Simply Wall St surfaced 95 more companies with equally compelling growth and insider ownership stories in the Fast Growing Stocks With High Insider Ownership screener. Use Simply Wall St to quickly identify and analyze the specific catalysts, insider activity and growth narratives that matter most to you so you can focus on your highest conviction ideas.
Take Control of Your Investment Journey
If Predictive Discovery or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Seeking Fresh Alternatives Before They Fly?
Markets move fast, and the strongest breakout stories rarely stay under the radar for long. Scan these fresh ideas before the crowd reacts and consider your options.
- Identify resilient companies with balance sheets that can absorb shocks and growth plans that still have momentum by screening the curated list of solid balance sheet and fundamentals (19 results).
- Track cash-generative AI stocks that are already past the initial hype phase and filter out story stocks that are burning cash using the focused 64 profitable AI stocks that aren't just burning cash.
- Review opportunities in critical metals by scanning a refined 29 best rare earth metal stocks that highlights producers tied to long term electrification and technology demand.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com